Materias dentro de su búsqueda.
Mostrando 1,301 - 1,320 Resultados de 58,773 Para Buscar '"Her"', tiempo de consulta: 1.50s Limitar resultados
  1. 1301
    “…However, pathologists usually use a semi-quantitative assessment method to assign HER2 scores for gastric cancer by repeatedly comparing hematoxylin and eosin (H&E) whole slide images (WSIs) with their HER2 immunohistochemical WSIs one by one under the microscope. …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    A Deep Learning Quantification Algorithm for HER2 Scoring of Gastric Cancer
  2. 1302
    “…Overexpression of human epidermal growth factor receptor 2 (HER2) occurs in approximately 15–20% of breast cancer cases. …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    The efficacy of tucatinib-based therapeutic approaches for HER2-positive breast cancer
  3. 1303
    “…SIMPLE SUMMARY: The development of several antiHuman Epidermal Growth Factor Receptor 2 (HER2) treatments over the last few years has improved the landscape of HER2-positive breast cancer. …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Targeted Therapeutic Options and Future Perspectives for HER2-Positive Breast Cancer
  4. 1304
    por Fong, Caroline, Chau, Ian
    Publicado 2022
    “…Human epidermal growth receptor 2 (HER2) overexpression of HER2 gene amplification is present in 20% of gastric cancers and defines a subset amenable to HER2-directed therapeutics. …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    HER2 Inhibition in Gastric Cancer—Novel Therapeutic Approaches for an Established Target
  5. 1305
    por Mayer, Claude-Hélène
    Publicado 2022
    “…The article presents findings on the coping skills, sense of coherence, and faith development in the life of Elizabeth Schuyler Hamilton which strongly influenced her resilience and support for others during her long and extraordinary life. …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Elizabeth Schuyler Hamilton in psychobiography: Sense of coherence and faith across her lifetime
  6. 1306
    “…In this sense, the clinical management of HER2 breast carcinomas (tumors with overexpression/amplification of the ErbB2/HER2 oncogene) is still a challenge. …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Novel Therapies and Strategies to Overcome Resistance to Anti-HER2-Targeted Drugs
  7. 1307
    “…Molecular docking of ligands with HER2, Src, PI3Kα, PI3KΔ, and PI3Kγ proteins was evaluated using MOE 2010. …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Synergistic Cytotoxic and Antimigratory Effect of Brazilein and Doxorubicin on HER2-Overexpressing Cells
  8. 1308
    “…Although targeted drugs improved the therapeutic effect of HER2-positive breast cancer, the long-term prognosis was still poor. …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Advances in Antibody-Drug Conjugates in the Treatment of HER2-Positive Breast Cancer
  9. 1309
    “…Although therapies based on the use of monoclonal anti-HER2 antibodies present clinical benefit for a subtype of patients with HER2-positive breast cancer, more than 50% of them are unresponsive to targeted therapies or they eventually relapse. …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Tumor-Infiltrating Lymphocytes and Immune Response in HER2-Positive Breast Cancer
  10. 1310
    “…Here, we used zebrafish genetics to investigate her9 and her6 gene function during craniofacial development. …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Distinct and redundant roles for zebrafish her genes during mineralization and craniofacial patterning
  11. 1311
    “…Breast cancer (BC) is caused by epigenetic modifications and genetic heterogeneity and exhibits various histological feature. HER2+ (Human epidermal growth factor receptor 2) is a more aggressive type of breast cancer, diagnosis and prognosis are difficult for HER2+ BC. …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Clinical updates on tyrosine kinase inhibitors in HER2-positive breast cancer
  12. 1312
    “…OBJECTIVE: Besides breast and gastric cancer, HER2 amplification/mutation are also found in lung adenocarcinoma (LUAD). …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Characteristics of the immunogenicity and tumor immune microenvironment in HER2-amplified lung adenocarcinoma
  13. 1313
    por Zhang, Huina, Peng, Yan
    Publicado 2022
    “…SIMPLE SUMMARY: The breakthrough in developing novel HER2-targeting antibody drug conjugates and identifying their clinical benefits in HER2-low breast cancer will dramatically revolutionize the clinical treatment landscape of HER2 negative breast cancers, as well as the pathologic evaluation of HER2 status in breast cancers. …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Current Biological, Pathological and Clinical Landscape of HER2-Low Breast Cancer
  14. 1314
    “…SIMPLE SUMMARY: One out of 8 breast cancers is of a particular type called “HER2-positive”, which is more aggressive and is treated by surgery and a medical treatment associating chemotherapy and a targeted drug against the protein HER2, possibly followed by radiotherapy and endocrine therapy. …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    STARD3: A New Biomarker in HER2-Positive Breast Cancer
  15. 1315
    “…The overexpression of the HER2 protein is generally evaluated by immunohistochemistry (IHC). …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Immunohistochemical HER2 Recognition and Analysis of Breast Cancer Based on Deep Learning
  16. 1316
    por Garg, Nidhi, Thorat, Mangesh A.
    Publicado 2023
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    HER2 expression should be routinely evaluated in DCIS to avoid under or overtreatment!
  17. 1317
    “…Overexpression of the human epidermal growth factor receptor‐2 (HER2/neu) protein is considered an important prognostic factor in breast cancer, but its role has not been confirmed in lung cancer. …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    The expression of HER2/neu in patients with lung cancer and its associated factors
  18. 1318
    “…Immunohistochemical (IHC) scores of 3 + or 2 + were termed “HER3-high”, while IHC scores of 1 + or 0 were designated as “HER3-low/zero”. …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Changes in HER3 expression profiles between primary and recurrent gynecological cancers
  19. 1319
    “…Human epidermal growth factor receptor 3 (HER3) is a member of the human epidermal growth factor receptors family, having as its main ligands neuregulins 1 and 2. …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Targeting HER3 for cancer treatment: a new horizon for an old target
  20. 1320
    “…Approximately half of breast cancers (BCs), historically categorized as human epidermal growth factor receptor 2 (HER2)-negative, have low expression of HER2 defined as an immunohistochemical (IHC) score of 1+ or 2+ with negative in situ hybridization. …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    The HER2-low revolution in breast oncology: steps forward and emerging challenges
Herramientas de búsqueda: RSS